Dang Shuang-Suo, Jia Xiao-Li, Cheng Yan-An, Chen Yun-Ru, Liu En-Qi, Li Zong-Fang
Department of Infectious Disease, Second Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China.
World J Gastroenterol. 2004 Aug 1;10(15):2295-8. doi: 10.3748/wjg.v10.i15.2295.
To assess the inhibitory effect of Huangqi Zhechong decoction on hepatic fibrosis in rats induced by CCl(4) plus alcohol and high fat low protein diet.
Male SD rats were randomly divided into hepatic fibrosis model group, control group and 3 treatment groups consisting of 12 rats in each group. Except for the normal control group, all the rats were subcutaneously injected with CCl(4) at a dosage of 3 mL/kg. In 3 treated groups, either high-dose group (9 mL/kg), or medium-dose group (6 mL/kg), or low-dose group (3 mL/kg) was daily gavaged with Huangqi Zhechong decoction, and saline vehicle was given to model and normal control rats. Enzyme-linked immunosorbent assay (ELISA) and biochemical examinations were used to determine the changes of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), laminin (LN), type-III-procollagen-N-peptide (PIIIP), and type IV collagen content in serum, and hydroxyproline (Hyp) content in liver after sacrificing the rats. Pathologic changes, particularly fibrosis were examined by hematoxylin and eosin (HE) and Van Gieson staining.
Compared with the model control group, serum ALT, AST, HA, LN, PIIIP and type IV collagen levels dropped markedly in Huangqi Zhechong decoction groups, especially in the medium-dose Huangqi Zhechong decoction group (1 954+/-576 U/L vs 759+/-380 U/L, 2 735+/-786 U/L vs 1 259+/-829 U/L, 42.74+/-7.04 ng/mL vs 20.68+/-5.85 ng/mL, 31.62+/-5.84 ng/mL vs 14.87+/-1.45 ng/mL, 3.26+/-0.69 ng/mL vs 1.47+/-0.46 ng/mL, 77.68+/-20.23 ng/mL vs 25.64+/-4.68 ng/mL, respectively) (P<0.05). The Hyp content in liver tissue was also markedly decreased (26.47+/-11.24 mg/mgprot vs 9.89+/-3.74 mg/mgprot) (P<0.01). Moreover, the stage of the rat liver fibrosis in Huangqi Zhechong decoction groups was lower than that in model group, and more dramatic drop was observed in medium-dose Huangqi Zhechong decoction group (P<0.01).
Huangqi Zhechong decoction can inhibit hepatic fibrosis resulted from chronic liver injure, retard the development of cirrhosis, and notably ameliorate the liver function. It may be a safe and effective therapeutic drug for patients with fibrosis.
评估黄芪蛰虫汤对四氯化碳加酒精及高脂低蛋白饮食诱导的大鼠肝纤维化的抑制作用。
雄性SD大鼠随机分为肝纤维化模型组、对照组和3个治疗组,每组12只。除正常对照组外,所有大鼠均皮下注射3 mL/kg剂量的四氯化碳。3个治疗组分别每日灌胃高剂量(9 mL/kg)、中剂量(6 mL/kg)或低剂量(3 mL/kg)的黄芪蛰虫汤,模型组和正常对照组给予生理盐水。采用酶联免疫吸附测定(ELISA)和生化检测方法,测定大鼠处死血清中丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、透明质酸(HA)、层粘连蛋白(LN)、III型前胶原N端肽(PIIIP)和IV型胶原含量,以及肝脏中羟脯氨酸(Hyp)含量。通过苏木精-伊红(HE)和Van Gieson染色检查病理变化,特别是纤维化情况。
与模型对照组相比,黄芪蛰虫汤各治疗组血清ALT、AST、HA、LN、PIIIP和IV型胶原水平均显著下降,尤其是中剂量黄芪蛰虫汤组(分别为1 954±576 U/L对759±380 U/L,2 735±786 U/L对1 259±829 U/L,42.74±7.04 ng/mL对20.68±5.85 ng/mL,31.62±5.84 ng/mL对14.87±1.45 ng/mL,3.26±0.69 ng/mL对1.47±0.46 ng/mL,77.68±20.23 ng/mL对25.64±4.68 ng/mL)(P<0.05)。肝组织中Hyp含量也显著降低(26.47±11.24 mg/mgprot对9.89±3.74 mg/mgprot)(P<0.01)。此外,黄芪蛰虫汤各治疗组大鼠肝纤维化程度低于模型组,中剂量黄芪蛰虫汤组下降更为显著(P<0.01)。
黄芪蛰虫汤可抑制慢性肝损伤所致的肝纤维化,延缓肝硬化发展,显著改善肝功能。它可能是一种治疗纤维化患者安全有效的治疗药物。